MTOR and lung cancer: Notably, rapamycin showed little beneficial effects in NOP56 KD KRAS wild-type H1703 xenografts (Fig. S5B, C), which mirrors the in vitro data and reinforces the selective activity of co-targeting NOP56/mTOR in KRAS-mutant lung cancer.